In this article AAPL Follow your favorite stocks CREATE FREE ACCOUNT The U.S. Supreme Court building on May 4, 2026 in Washington, DC. Andrew Harnik | Getty Images The U.S. Supreme Court rejected on Wednesday Apple's request to temporarily block a judicial order that found the iPhone maker in violation of sweeping court-mandated changes to its lucrative App Store as part of an antitrust lawsuit by...
In this article AAPL Follow your favorite stocks CREATE FREE ACCOUNT The U.S. Supreme Court building on May 4, 2026 in Washington, DC. Andrew Harnik | Getty Images The U.S. Supreme Court rejected on Wednesday Apple's request to temporarily block a judicial order that found the iPhone maker in violation of sweeping court-mandated changes to its lucrative App Store as part of an antitrust lawsuit by "Fortnite" maker Epic Games. Justice Elena Kagan, on behalf of the court, declined to pause a ruling by the San Francisco-based 9th U.S. Circuit Court of Appeals that deemed Apple in contempt in the Epic lawsuit contesting App Store fees. Apple had sought the delay to give it time to file a full Supreme Court appeal of the 9th Circuit decision. Apple and Epic have clashed for years over the rules governing Apple's App Store. The contempt ruling and the scope of Apple's court-ordered obligations are the latest issues in the dispute to reach the Supreme Court. Apple has said the 9th Circuit decision would affect how millions of app purchases are made. Epic Games won the contempt order last year as part of litigation it brought in 2020 seeking to loosen Apple's control over transactions in applications that use the company's iOS operating system and its restrictions on how apps are distributed to consumers. Apple mostly defeated Epic's lawsuit, but was required in a 2021 court injunction to let developers include links in their apps directing users to non-Apple payment methods. Apple allowed the links but adopted new restrictions, including a 27% commission on developers for purchases made on payment systems outside the App Store within seven days of clicking a link. Apple charges developers a 30% commission for purchases within the App Store. Epic argued that the new 27% commission flouted the earlier injunction. In 2025, U.S. District Judge Yvonne Gonzalez Rogers found Apple in civil contempt for violating the injunction. The 9th Circuit in December upheld the judge's conte...
Earnings Call Insights: Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Management View "This year is expected to be transformative with growing revenue and multiple new drug approvals" (Founder, President, CEO & Director Emil Kakkis), adding, "We're on track to well exceed $700 million in revenue from our global commercial business" and describing 2027 as "paving the path to profitability in 2027."...
Earnings Call Insights: Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Management View "This year is expected to be transformative with growing revenue and multiple new drug approvals" (Founder, President, CEO & Director Emil Kakkis), adding, "We're on track to well exceed $700 million in revenue from our global commercial business" and describing 2027 as "paving the path to profitability in 2027." "We have a PDUFA date for two gene therapies" (CEO Kakkis) and said the company is "manufacturing our gene therapy products in our new facility in Bedford, Massachusetts." "We have 66 patients on therapy for an average of 3 years and with the longest approaching 5 years" (CEO Kakkis) and said GTX-102 has shown "continuing and improving benefits across multiple domains and with a favorable safety profile." "In Latin America, approximately 30 patients began commercial therapy in the first quarter, bringing the total number of patients on Crysvita to more than 950 in the region" (Executive VP & Chief Commercial Officer Erik Harris). "In the first quarter, our North American team generated more than 30 start forms" for Dojolvi, and "we now have more than 675 patients on reimbursed therapy" in North America (CCO Harris). "My team is preparing for two new product launches, DTX401 with a PDUFA date of August 23, 2026, and UX111 with a PDUFA date of September 19, 2026" (CCO Harris). "Total revenue for the first quarter of 2026 was $136 million" and "we are reaffirming the revenue guidance we provided in February" (Executive VP of Corporate Strategy & CFO Howard Horn). Outlook "Total revenue in 2026 is expected to be between $730 million and $760 million" and "excludes potential revenue from new product launches" (CFO Horn). "Crysvita revenue is expected to be between $500 million and $520 million" with the range reflecting "expected timing of ordering patterns in Brazil that we anticipate will normalize in 2027" (CFO Horn). "Dojolvi revenue is expected to be between $100 million a...
I don't think I need to tell you that things are getting a little chaotic out there in the world. The Russia-Ukraine war is raging into its fifth year. There might be a ceasefire in the war between Iran, the United States, and Israel, but it's tenuous at best. Who knows what will happen next? I certainly don't. Maybe we'll be extremely lucky and countries around the world will finally give peace a...
I don't think I need to tell you that things are getting a little chaotic out there in the world. The Russia-Ukraine war is raging into its fifth year. There might be a ceasefire in the war between Iran, the United States, and Israel, but it's tenuous at best. Who knows what will happen next? I certainly don't. Maybe we'll be extremely lucky and countries around the world will finally give peace a chance. Probably not. But a guy can hope, right? The best thing you can do for your portfolio right now is hedge it against the chaos across the world and across the markets with Rheinmetall (OTC: RNMBY) , which is shaping up to be one of the best defense industry plays for an uncertain future. Continue reading
sankai/E+ via Getty Images Market Commentary Global fixed income markets moved sharply lower during March 2026 as the conflict in Iran disrupted what had been a broadly constructive start to the quarter. Higher energy prices rekindled inflation concerns, pushing yields higher and presenting a challenging policy environment for central banks around the world. Markets largely abandoned expectations ...
sankai/E+ via Getty Images Market Commentary Global fixed income markets moved sharply lower during March 2026 as the conflict in Iran disrupted what had been a broadly constructive start to the quarter. Higher energy prices rekindled inflation concerns, pushing yields higher and presenting a challenging policy environment for central banks around the world. Markets largely abandoned expectations of U.S. Federal Reserve rate cuts and began pricing in multiple rate hikes by the European Central Bank and Bank of England. The Reserve Bank of Australia began raising rates, while the Central Bank of Brazil moved in the opposite direction, cutting them. This divergence, driven by differing inflation dynamics and varying exposures to the Middle East, contributed to notable volatility across global rates and currencies. During the first quarter, the best-performing currencies were generally those of commodity exporters, such as the Australian dollar, Brazilian real, and Norwegian krone. Global credit markets were relatively resilient, with investment-grade spreads widening modestly but remaining near historically tight levels. Performance1 Total Returns (%) Average Annual Total Returns 3 Months YTD 1 Year 3 Years 5 Years 10 Years Since Inception (12/5/2012) Global Bond Fund — Class I -0.21 -0.21 7.22 6.70 3.24 4.88 3.75 Global Bond Fund — Class X -0.19 -0.19 7.40 6.78 3.30 4.91 3.77 Bloomberg Global Aggregate Bond Index (USD Hedged) -0.15 -0.15 3.49 4.07 0.81 2.05 2.41 Click to enlarge Returns represent past performance and do not guarantee future results. Investment return and share price will fluctuate with market conditions, and investors may have a gain or loss when shares are sold. Mutual Fund performance changes over time and currently may be significantly lower than stated above. Performance is updated and published monthly. Current month-end performance can be obtained at dodgeandcox.com or by calling 800-621-3979. Portfolio Strategy Grounded in our valuation discip...
A lot of people breathe a sigh of relief when they sign up for Medicare, thinking that from that point onward, their healthcare costs will be minimal. But there are numerous costs associated with Medicare , including premiums for Part B (and sometimes Part D and Medicare Advantage), coinsurance, and deductibles. The problem is that while your monthly premiums may be fairly predictable (at least wi...
A lot of people breathe a sigh of relief when they sign up for Medicare, thinking that from that point onward, their healthcare costs will be minimal. But there are numerous costs associated with Medicare , including premiums for Part B (and sometimes Part D and Medicare Advantage), coinsurance, and deductibles. The problem is that while your monthly premiums may be fairly predictable (at least within each calendar year), it's hard to estimate your remaining costs. After all, you don't know what your healthcare needs will look like from year to year. But in some cases, you could be looking at thousands of dollars extra if you need a series of procedures or wind up admitted to the hospital. Image source: Getty Images. Continue reading
Earnings Call Insights: Koninklijke Philips N.V. (PHG) Q1 2026 Management View "We started '26 with a clear proof that our strategy is delivering, growth, margin expansion and strong order momentum despite the volatile environment" (President, CEO & Chairman of the Board of Management Roy Jakobs). "Order intake grew 6%" and "Comparable sales increased 4%" with "Adjusted EBITDA margin improved by 4...
Earnings Call Insights: Koninklijke Philips N.V. (PHG) Q1 2026 Management View "We started '26 with a clear proof that our strategy is delivering, growth, margin expansion and strong order momentum despite the volatile environment" (President, CEO & Chairman of the Board of Management Roy Jakobs). "Order intake grew 6%" and "Comparable sales increased 4%" with "Adjusted EBITDA margin improved by 40 basis points to 9%, despite higher tariffs" (President, CEO & Chairman of the Board of Management Jakobs). "We expect regulatory clearance in 2027" for "the industry's first helium-free 3.0T MR systems" and Philips said it had "installed more than 2,200 systems globally, saving over 6 million liters of helium" (President, CEO & Chairman of the Board of Management Jakobs). "This segment delivered another quarter of broad-based growth" and Philips cited "adding more than 3,000 distribution points in Europe" in Personal Health, alongside expanded retail listings (President, CEO & Chairman of the Board of Management Jakobs). "Adjusted diluted earnings per share from continuing operations were EUR 0.23" and "Free cash flow in Q1 was an inflow of EUR 28 million" (Executive VP, CFO & Member of Board of Management Charlotte Hanneman). "We ended the first quarter with EUR 2.6 billion in cash" and "Net debt was EUR 5.5 billion" (Executive VP, CFO & Member of Board of Management Hanneman). "In April, we signed a long-term strategic partnership with WellSpan Health in the U.S." and Philips also highlighted a "5-year enterprise service agreement" with AdventHealth (President, CEO & Chairman of the Board of Management Jakobs). Outlook Philips reiterated: "We expect comparable sales growth of 3% to 4.5%" for 2026 (Executive VP, CFO & Member of Board of Management Charlotte Hanneman). Philips reiterated: "we reiterate our full year adjusted EBITDA margin guidance range of between 12.5% and 13%" and "Our full year free cash flow outlook also remains unchanged at between EUR 1.3 billion an...
Earnings Call Insights: Amcor plc (AMCR) Q3 2026 Management View "Our financial performance in the third quarter was in line with expectations" and "Adjusted EPS of $0.96 per share was up 6% year-over-year," Peter Konieczny (CEO & Director) said, adding that the company is "making substantial progress" on divesting "noncore businesses" after the Berry combination. "We made important progress on ou...
Earnings Call Insights: Amcor plc (AMCR) Q3 2026 Management View "Our financial performance in the third quarter was in line with expectations" and "Adjusted EPS of $0.96 per share was up 6% year-over-year," Peter Konieczny (CEO & Director) said, adding that the company is "making substantial progress" on divesting "noncore businesses" after the Berry combination. "We made important progress on our portfolio optimization actions with 4 additional sale agreements reached over the last 3 months" and "The combined transaction value from these 6 divestitures is approximately $500 million," CEO Konieczny said. He added: "All cash proceeds will be used to reduce debt" and "the net impact on EPS is not expected to be material." On integration benefits, CEO Konieczny said, "Synergy delivery continues to accelerate, reaching $77 million in the quarter and $170 million for the first 9 months," and he stated, "we will deliver $270 million of synergies in fiscal 2026, ahead of our initial $260 million year 1 target." Addressing geopolitical and inflation concerns, CEO Konieczny said, "we're not expecting the Middle East conflict to have any material impact on our Q4 earnings," while also noting, "we have made choices about working capital management, primarily inventory through the fourth quarter" and "we now expect free cash flow to be in the range of $1.5 billion to $1.6 billion." Stephen Scherger (CFO & Executive VP) said, "We are confident that we will deliver $270 million in fiscal 2026 and $650 million cumulatively over 3 years," and added that "growth synergies continue to track well against our $280 million 3-year annualized revenue target with annualized revenue now exceeding $110 million." CFO Scherger announced reporting changes: "Effective in 2027, we will transition our fiscal year-end from June 30 to December 31" and "we will have a 6-month reporting period from July 1, 2026, through December 31, 2026." He also said, "beginning in 2027, we will initiate the migrat...